Cara Therapeutics, CARA known for its research on cannabinoid receptor agonists for the relief of inflammatory and neuropathic pain, will host a virtual research and development event on Friday, March 11 from 1:00 to 2:00 p.m. ET. The presentation will focus on the initiation of oral difelikefalin Phase 3 programs for the treatment of pruritus in patients with atopic dermatitis and non-dialysis dependent chronic kidney disease.
An interactive Q&A session will follow the presentation.
Presenters will include:
Christopher Posner, president & CEO and director of Cara Therapeutics
- Joana Goncalves, MD, chief medical officer of Cara Therapeutics
- Brian Kim, MD, MTR,
- Jonathan Silverberg, MD, Ph.D., MPH
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Top Cannabis Event In New Jersey
Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!